- Home
- KALA vs WYY Comparison
KALA vs WYY Comparison
Compare KALA & WYY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALA
- WYY
- Stock Information
- Founded
- KALA 2009
- WYY 1991
- Country
- KALA United States
- WYY United States
- Employees
- KALA N/A
- WYY N/A
- Industry
- KALA Biotechnology: Pharmaceutical Preparations
- WYY EDP Services
- Sector
- KALA Health Care
- WYY Technology
- Exchange
- KALA Nasdaq
- WYY Nasdaq
- Market Cap
- KALA 26.2M
- WYY 29.5M
- IPO Year
- KALA 2017
- WYY 1998
- Fundamental
- Price
- KALA $8.58
- WYY $3.90
- Analyst Decision
- KALA Strong Buy
- WYY Strong Buy
- Analyst Count
- KALA 3
- WYY 1
- Target Price
- KALA $14.00
- WYY $7.00
- AVG Volume (30 Days)
- KALA 183.0K
- WYY 99.7K
- Earning Date
- KALA 08-08-2025
- WYY 08-14-2025
- Dividend Yield
- KALA N/A
- WYY N/A
- EPS Growth
- KALA N/A
- WYY N/A
- EPS
- KALA N/A
- WYY N/A
- Revenue
- KALA N/A
- WYY $144,421,640.00
- Revenue This Year
- KALA N/A
- WYY $9.05
- Revenue Next Year
- KALA N/A
- WYY $12.24
- P/E Ratio
- KALA N/A
- WYY N/A
- Revenue Growth
- KALA N/A
- WYY 16.25
- 52 Week Low
- KALA $2.92
- WYY $2.19
- 52 Week High
- KALA $11.20
- WYY $6.25
- Technical
- Relative Strength Index (RSI)
- KALA 67.01
- WYY 65.45
- Support Level
- KALA $7.38
- WYY $3.25
- Resistance Level
- KALA $7.71
- WYY $3.87
- Average True Range (ATR)
- KALA 0.79
- WYY 0.31
- MACD
- KALA 0.03
- WYY 0.07
- Stochastic Oscillator
- KALA 92.58
- WYY 87.89
About KALA KALA BIO Inc.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.
About WYY WidePoint Corporation
WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.